Jitongning Tablets
- Generic Name
- Jitongning Tablets
A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo
Phase 3
Recruiting
- Conditions
- Ankylosing Spondylitis
- Interventions
- Drug: a simulated agent of Jitongning tablets
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Tasly Pharmaceutical Group Co., Ltd
- Target Recruit Count
- 408
- Registration Number
- NCT06000956
- Locations
- 🇨🇳
Yunnan Province Hospital of Traditional Chinese Medicine, Kunming, Yunnan, China
🇨🇳Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, Beijing, China
🇨🇳The First Hospital of Lanzhou University, Lanzhou, Gansu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath